高渗盐水在重型颅脑创伤患者颅内压与脑灌注压联合负荷控制上优于甘露醇
基于纽约州TBI-trac®数据库的病例对照研究,纳入仅使用甘露醇或高渗盐水一种高渗制剂的重型颅脑创伤患者,按2周死亡率相关因素进行1:1和1:2匹配。高渗盐水组颅内压高和脑灌注压低的联合负荷(天数、百分比、总时长)均显著低于甘露醇组,1:2匹配结果一致。
要点
- 高渗盐水组颅内压高且脑灌注压低的总天数(0.6±0.8 vs 2.4±2.3天,P<.01)显著低于甘露醇组。
- 高渗盐水组颅内压高且脑灌注压低的天数百分比(8.8±10.6 vs 28.1±26.9%,P<.01)显著低于甘露醇组。
- 高渗盐水组颅内压高且脑灌注压低的总时长(11.12±14.11 vs 30.56±31.89小时,P=.01)显著低于甘露醇组。
核心结论
- 高渗盐水团注治疗在减轻重型颅脑创伤患者颅内高压及相关低灌注的联合负荷方面似乎优于甘露醇。
研究设计与样本
- 采用纽约州TBI-trac®数据库(脑创伤基金会,纽约州纽约市)前瞻性收集数据的病例对照研究。
- 纳入仅接受甘露醇或高渗盐水一种高渗制剂治疗颅内压升高的患者,按2周死亡率相关因素(年龄、格拉斯哥昏迷评分、瞳孔反应性、低血压、异常计算机断层扫描、开颅手术)进行1:1和1:2匹配。
- 1:1比较有25对匹配;1:2比较为24例高渗盐水患者匹配48例甘露醇患者。
主要发现
- 两组累积中位渗透压剂量相似。
- 高渗盐水组相比甘露醇组,颅内压高(>25 mm Hg)且脑灌注压低(<60 mm Hg)的总天数(0.6±0.8 vs 2.4±2.3天,P<.01)显著更低。
- 高渗盐水组相比甘露醇组,颅内压高且脑灌注压低的天数百分比(8.8±10.6 vs 28.1±26.9%,P<.01)显著更低。
- 高渗盐水组相比甘露醇组,颅内压高且脑灌注压低的总时长(11.12±14.11 vs 30.56±31.89小时,P=.01)显著更低。
- 上述结果在1:2匹配比较中重复验证。
关键数值与推荐
- 主要终点为颅内压高(>25 mm Hg)和脑灌注压低(<60 mm Hg)的联合负荷。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertonic saline (HTS) and mannitol are effective in reducing intracranial pressure (ICP) after severe traumatic brain injury (TBI). However, their simultaneous effect on the cerebral perfusion pressure (CPP) and ICP has not been studied rigorously. OBJECTIVE: To determine the difference in effects of HTS and mannitol on the combined burden of high ICP and low CPP in patients with severe TBI. METHODS: We performed a case-control study using prospectively collected data from the New York State TBI-trac® database (Brain Trauma Foundation, New York, New York). Patients who received only 1 hyperosmotic agent, either mannitol or HTS for raised ICP, were included. Patients in the 2 groups were matched (1:1 and 1:2) for factors associated with 2-wk mortality: age, Glasgow Coma Scale score, pupillary reactivity, hypotension, abnormal computed tomography scans, and craniotomy. Primary endpoint was the combined burden of ICPhigh (> 25 mm Hg) and CPPlow (< 60 mm Hg). RESULTS: There were 25 matched pairs for 1:1 comparison and 24 HTS patients matched to 48 mannitol patients in 1:2 comparisons. Cumulative median osmolar doses in the 2 groups were similar. In patients treated with HTS compared to mannitol, total number of days (0.6 ± 0.8 vs 2.4 ± 2.3 d, P < .01), percentage of days with (8.8 ± 10.6 vs 28.1 ± 26.9%, P < .01), and the total duration of ICPhigh + CPPlow (11.12 ± 14.11 vs 30.56 ± 31.89 h, P = .01) were significantly lower. These results were replicated in the 1:2 match comparisons. CONCLUSION: HTS bolus therapy appears to be superior to mannitol in reduction of the combined burden of intracranial hypertension and associated hypoperfusion in severe TBI patients.
引用
- Mangat HS, Wu X, Gerber LM, et al. Hypertonic Saline is Superior to Mannitol for the Combined Effect on Intracranial Pressure and Cerebral Perfusion Pressure Burdens in Patients With Severe Traumatic Brain Injury. Neurosurgery. 2020. PMID: 30877299. doi:10.1093/neuros/nyz046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。